ONCO$0.528-2.73%
Onconetix, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$2.77M
Float & O/S:5.24M / 5.24M
Inst Own:0.0%
DilutionScan read 30 of Onconetix, Inc.'s SEC filings and found 7 warrant series, 5 convertibles, 1 ATM program, 2 equity lines, 8 S-1 registrations and 4 completed offerings on file for ONCO. The latest dilution event on file is a registration statement on Sep 3, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
ONCO
Going-concern warning and reverse splits
Snapshot
Onconetix is a distressed micro-cap biotech fighting for survival. FY 2025 revenue collapsed 68% to $815K, while the company burned $9.7M in free cash flow. With only $5.2M in the bank, the cash runway is under one month.
What's Happening Right Now
- : Onconetix filed an S-1 registration disclosing substantial doubt about its ability to continue as a going concern, while registering up to 100 million shares for resale under an equity line.
- : The board approved a 1-for-10 reverse stock split effective May 21, 2026, the second reverse split in three months.
- : Subsidiary Proteomedix initiated a multi-center clinical validation study for its Proclarix diagnostic test in collaboration with Labcorp.
- : Onconetix announced it entered a definitive agreement to acquire Realbotix LLC, a subsidiary developing humanoid robots and AI vision systems.
